Leide Biotech Secures ￥10 Million in Angel Round

(VCBeat) May. 21, 2021 -- Recently, Guangzhou Leide Bioscience Co., Ltd.（"Leide Biotech"）, an international leader focusing on immunodiagnostics and TB infection screening, announced the completion of a Series B2 round of tens of millions, with participation from Luxin Venture Capital Group and Qidao Capital. The funds raised will be used to build a marketing team, develop innovative products for immunodiagnostics, and expand reagent production.

Immunodiagnosis and treatment is an emerging field with rapid growth in recent years, which is leading the medical industry. Dr. Lou Jianrong, Chairman and General Manager of Leide Biotech, said, "The immune system has important functions of external defense against the invasion of microorganisms, internal monitoring of cell mutations and stabilizing the body's internal environment. Many major autoimmune diseases, such as infection and tumors, are closely related to the imbalance of immunity. Leide Biotech has established an in vitro diagnostic system as the first of its kind in the world, with a dynamic diagnosis of cell function as the core, combined with static biomarker detection, to achieve an early, comprehensive and accurate diagnosis of major immune-mediated diseases."

Leide Biotech is an innovative in vitro diagnostic company that focuses on DSCIDS -- a new generation of in vitro diagnostic technology. DSCIDS breaks through the limitations of existing molecular diagnostic technology and uses cell function analysis to accurately diagnosis complex immune-mediated diseases.

Leide Biotech's business covers a wide variety of fields from infectious diseases, immune function evaluation and immunotherapy for autoimmune diseases to tumors and organ transplants. We have an integrated strategic layout that focuses on the development of in vitro diagnostic reagents, raw materials and special clinical immunoassay services.

Leide Biotech is committed to the R&D of IVD products of immune-mediated diseases to provide high-quality products and services that improve human health.

Lucion is the largest and most influential venture capital firm in Shandong Province, which is controlled by Shandong Luxin Investment Holding Group Co., Ltd. Its portfolios include well-known medical and health companies such as 3D Medicines, RemeGen, ABclonal, TCR2 Therapeutics, etc.

Funway Capital is a professional equity investment fund in the medical industry. The fund investors include a number of listed companies in the medical industry, government guide funds, overseas investors, etc. It has industrial resources covering in vitro diagnosis, new drug research and development, CRO/CMO, etc.